
Opinion|Videos|October 14, 2025
Balancing Treatment Burden, Access Barriers, and Future Research of BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding protocol-driven step therapy requirements, as future comparative effectiveness trials and real-world evidence will better inform individualized patient care strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
A Milestone in Vitiligo: Clinical Efficacy and Long-Term Repigmentation Trends
4
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
5



























